Navigation Links
Connecticut State Medical Society and Genomas Co-Sponsor Forum on DNA-Guided Medicine and the Path to Personalized Health Care
Date:9/24/2008

FDA Expert on Pharmacogenomics Offers a Prescription for Progress

WATERBURY, Conn., Sept. 24 /PRNewswire/ -- The Connecticut State Medical Society is joining with Genomas(R), a biomedical company advancing DNA-guided medicine and personalized healthcare, to co-sponsor a symposium -- DNA-Guided Medicine and the Path to Personalized Health Care -- being held today at the Society's annual meeting. Hartford Hospital is providing continuing medical education credits for physicians attending the meeting.

Lawrence J. Lesko, Ph.D., Director of the Office of Clinical Pharmacology, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, will discuss FDA Initiatives in Personalized Medicine: Advancing Individualized Drug Therapy.

Dr Lesko commented: "The U.S. Department of Health and Human Services and the FDA have prioritized personalized medicine as one of their mission goals for public health. I am glad to participate in this event with the Connecticut Medical Society, Hartford Hospital and Genomas to bring these initiatives to physicians who are in an important position to implement them in their clinical practice. Connecticut is poised to become one of the national leaders in adoption of personalized medicine, and I am thrilled to join ranks with these local efforts as exemplary to improving the healthcare system as a whole."

Gualberto Ruano, M.D., Ph.D., President and CEO of Genomas, will speak about Progress Towards DNA-Guided Medicine in Clinical Practice: Case Studies in Cardiology and Psychiatry. Examples in these two therapeutic areas include statins and atypical antipsychotics.

Dr. Ruano commented: "We are privileged to partner with the Connecticut State Medical Society to convene the physicians in our state for this forum. The presence of the FDA is an indication of the national impact of the programs in DNA-Guided Medicine that Genomas has spearheaded in Connecticut with Hartford Hospital and the Hospital of Central Connecticut. Together, we are bringing personalized healthcare to our patients today, and setting the pathway to utilization of DNA-Guided Medicine as the standard of care in cardiovascular and psychiatric clinical practice."

ABOUT GENOMAS

Genomas Inc. is a biomedical company advancing DNA-guided medicine and personalized healthcare. The company develops revolutionary PhyzioType(TM) Systems for DNA-guided diagnosis and prevention of metabolic disorders induced by drugs in cardiovascular and psychiatric medicine. PhyzioType Systems are designed to provide physicians with the unprecedented capability to select for each patient the safest drug treatment to enhance compliance. Genomas is located in Hartford, CT on the campus of Hartford Hospital. For more information, please visit http://www.genomas.net

ABOUT PHYZIOTYPE CLINICAL MANAGEMENT SYSTEMS

PhyzioType Systems are composed of an ensemble of inherited DNA polymorphisms genotyped by arrays and interpreted by a biomathematical algorithm in order to convey to physicians predicted comparisons of side effect risk among drugs for the individual patient. To date, Genomas has secured $3.1 million from NIH Small Business Innovation Research (SBIR) for PhyzioType System product development.


'/>"/>
SOURCE Genomas Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Connecticut Technology Council to Recognize Fast Growing Technology Companies
2. Connecticut BioBus Travels to State Capitol on April 24 for Tours and Experiments with Visiting Students
3. Exposure to Agent Orange linked to prostate cancer in Vietnam veterans
4. JD Technologies, LLC Selected by FCT Ingenieurkeramik GmbH to Represent Their High Performance Ceramic Expertise In the United States
5. NC State engineers discover nanoparticles can break on through
6. Department of Justice Provides States With Funding for Testing in Postconviction Cases
7. Orange Coast Urology Offers Advanced In-Office Patient EVOLVE(R) Laser Prostate Treatment
8. Revolutionary New In-Office EVOLVE(R) Laser Prostate Treatment Available Throughout Western Oregon
9. InVitria Further Strengthens Sales Team with Promotion of Brandy Sargent to Account Manager - Western United States
10. States First Single Incision Robotic Kidney Removal Performed at Henry Ford Hospital
11. Baxter Announces Licensing Agreement for Innocolls Gentamicin Surgical Implant in the United States
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/16/2017)... , ... January 16, 2017 , ... ... the prestigious Tibbetts Award from the U.S. Small Business Administration. The ... created a significant economic or social impact […] and are considered the best of ...
(Date:1/13/2017)... Jan 13, 2017 Research and Markets has announced ... their offering. ... biopolymers market to grow at a CAGR of 16.83% during the period ... growth prospects of the global biopolymers market for 2017-2021. To calculate the ... sales of biopolymer products. The report also includes a a discussion of ...
(Date:1/12/2017)... ... January 12, 2017 , ... Each year, Crain’s Detroit Business News ranks the ... evaluates the patent estate of a company, its impact and significance, and the likelihood ... the way in technologies that transform energy sources such as low dose X-ray and ...
(Date:1/12/2017)... 12, 2017   Protein Sciences Corporation , ... Flublok Influenza Vaccine ®, announced today that ... good safety results and induced strong neutralizing antibodies ... product is expected to advance into human clinical ... the Institute of Technology in Immunobiologicals of the ...
Breaking Biology Technology:
(Date:12/7/2016)... 2016   Avanade is helping Williams Martini ... in history, exploit biometric data in order to critically ... the competitive edge against their rivals after their impressive, ... Avanade has worked with Williams during the 2016 season ... (heart rate, breathing rate, temperature and peak acceleration) for ...
(Date:12/6/2016)... , Dec. 6, 2016 Valencell , ... today it has seen a third consecutive year of ... sensor technology in 2016 with a 360 percent increase ... year. This increase was driven by sales of its ... robust interest in its technology for hearables for fitness ...
(Date:12/2/2016)... The report "Biometric Vehicle Access ... (Iris Recognition System), Vehicle Type (Passenger Car, Battery ... 2021", published by MarketsandMarkets, the market is estimated ... is projected to grow to USD 854.8 Million ...      (Logo: http://photos.prnewswire.com/prnh/20160303/792302) ...
Breaking Biology News(10 mins):